Ranked #3,740 of 8,699 institutional investors
Catalio Capital Management, LP
New York, NY
$472M
US stock portfolio at live prices · today −$5.4M (−1.14%)
Live prices, last trade 11:32 AM ET
- Value at quarter end (Q3 2026)
- $538M
- Change from Q2 2026
- +$6.2M (+1.17%)
- Positions
- 44 · 13 new, 5 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$39.3M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesAVLN 10.1%BBIO 6.96%BMY 6.30%JNJ 5.72%PBLS 4.86%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| AVLN Avalyn Pharma Inc. | 1,698,851 | $47.9M | 10.1% | Added +1% |
| BBIO BridgeBio Pharma, Inc. | 425,111 | $32.8M | 6.96% | Reduced −7% |
| BMY Bristol-Myers Squibb Company | 499,716 | $29.7M | 6.30% | Added +21% |
| JNJ Johnson & Johnson | 99,496 | $27.0M | 5.72% | Reduced −28% |
| PBLS Parabilis Medicines, Inc. | 824,043 | $22.9M | 4.86% | Unchanged |
| SEPN Septerna, Inc. | 454,015 | $17.8M | 3.76% | Reduced −15% |
| EW Edwards Lifesciences Corporation | 161,121 | $16.6M | 3.52% | Added +29% |
| DFTX Definium Therapeutics, Inc. | 497,964 | $14.5M | 3.07% | Reduced −12% |
| PTGX Protagonist Therapeutics, Inc. | 112,418 | $13.8M | 2.92% | Added +5% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 315,247 | $13.5M | 2.86% | New |
| GH Guardant Health, Inc. | 92,579 | $13.5M | 2.86% | New |
| AMLX Amylyx Pharmaceuticals, Inc. | 505,882 | $13.1M | 2.77% | New |
| IRON Disc Medicine, Inc. | 172,709 | $12.9M | 2.74% | Added +8% |
| CELC Celcuity Inc. | 230,609 | $12.6M | 2.67% | New |
| MANE Veradermics Inc | 95,646 | $11.6M | 2.46% | Added +109% |
| RARE Ultragenyx Pharmaceutical Inc. | 601,760 | $10.0M | 2.13% | Added +90% |
| CRVS Corvus Pharmaceuticals, Inc. | 1,021,499 | $9.9M | 2.10% | Reduced −5% |
| RYTM Rhythm Pharmaceuticals, Inc. | 85,614 | $9.7M | 2.06% | New |
| SNDX Syndax Pharmaceuticals, Inc. | 1,023,510 | $9.1M | 1.94% | Reduced −16% |
| BMRN BioMarin Pharmaceutical Inc. | 144,971 | $8.9M | 1.88% | New |
| TXG 10x Genomics, Inc. | 164,029 | $8.7M | 1.83% | New |
| MLYS Mineralys Therapeutics, Inc. | 583,364 | $8.2M | 1.73% | Reduced −10% |
| ODTX Odyssey Therapeutics, Inc. | 457,839 | $8.0M | 1.69% | Unchanged |
| FDMT 4D Molecular Therapeutics, Inc. | 684,753 | $7.3M | 1.54% | Added +45% |
| ANNX Annexon, Inc. | 1,986,806 | $6.4M | 1.36% | New |
| IMCR Immunocore Holdings plc | 211,985 | $5.6M | 1.20% | Added +43% |
| KLRA Kailera Therapeutics, Inc. | 468,750 | $5.4M | 1.14% | Unchanged |
| COGT Cogent Biosciences, Inc. | 167,716 | $4.5M | 0.96% | New |
| GPCR Structure Therapeutics Inc. | 260,109 | $4.3M | 0.91% | Reduced −6% |
| NKTR Nektar Therapeutics | 126,817 | $4.0M | 0.84% | New |
| KARD Kardigan, Inc. | 312,500 | $3.8M | 0.81% | Unchanged |
| NTRA Natera, Inc. | 12,530 | $3.5M | 0.74% | Reduced −85% |
| HTFL Heartflow, Inc. | 74,969 | $3.4M | 0.73% | Reduced −87% |
| KRSA Korsana Biosciences, Inc. | 87,702 | $3.3M | 0.70% | New |
| ELDN Eledon Pharmaceuticals, Inc. | 1,637,114 | $2.9M | 0.62% | Reduced −3% |
| FRNM Freenome, Inc. | 158,170 | $1.5M | 0.32% | New |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 699,532 | $1.3M | 0.27% | Added +120% |
| TARA Protara Therapeutics, Inc. | 512,287 | $1.2M | 0.25% | Reduced −2% |
| HYPR Hyperfine, Inc. | 1,303,155 | $645K | 0.14% | Reduced −1% |
| OM Outset Medical, Inc. | 107,456 | $313K | <0.1% | Reduced −9% |
| MGX Metagenomi Therapeutics, Inc. | 528,993 | $305K | <0.1% | Unchanged |
| ADRX ADARx Pharmaceuticals, Inc. | 11,357 | $160K | <0.1% | New |
| FTH Faeth Therapeutics, Inc. | 14,718 | $127K | <0.1% | Unchanged |
| KPTIQ Karyopharm Therapeutics Inc. | 976,191 | $33K | <0.1% | Added +4% |